Abstract OT1-1-11: DETECT III - A multicenter, randomized, phase III trial to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells

Tumor Cells ◽

Circulating Tumor Cells ◽

Standard Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial

OT1-02-06: DETECT III – A Multicenter, Randomized, Phase III Study To Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2−Negative Metastatic Breast Cancer and HER2−Positive Circulating Tumor Cells.

10.1158/0008-5472.sabcs11-ot1-02-06 ◽

2011 ◽

Cited By ~ 1

Author(s):

CA Melcher ◽

W Janni ◽

U Ortmann ◽

B Jäger ◽

B Rack ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Standard Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

191 DETECT III – a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells

European Journal of Cancer ◽

10.1016/s0959-8049(12)70259-9 ◽

2012 ◽

Vol 48 ◽

pp. S95-S96

Author(s):

C.A. Melcher ◽

W. Janni ◽

B. Rack ◽

V. Muller ◽

A. Schneeweiss ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Standard Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

Abstract PD3-12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial

10.1158/1538-7445.sabcs20-pd3-12 ◽

2021 ◽

Author(s):

Tanja Fehm ◽

Volkmar Mueller ◽

Maggie Banys-Paluchowski ◽

Peter A Fasching ◽

Thomas WP Friedl ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Phase Iii ◽

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

Breast Cancer Research and Treatment ◽

10.1007/s10549-012-2045-1 ◽

2012 ◽

Vol 134 (1) ◽

pp. 283-289 ◽

Cited By ~ 70

Author(s):

Marta Pestrin ◽

Silvia Bessi ◽

Fabio Puglisi ◽

Alessandro M. Minisini ◽

Giovanna Masci ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Single Agent ◽

Metastatic Breast ◽

Proof Of Concept ◽

Her2 Positive ◽

Multicenter Phase

PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-pd05-07 ◽

2011 ◽

Author(s):

EM Olson ◽

LM Flores ◽

JS Najita ◽

C Curley ◽

J Jeong ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker

BMC Cancer ◽

10.1186/1471-2407-13-202 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 41

Author(s):

Yi Liu ◽

Qian Liu ◽

Tao Wang ◽

Li Bian ◽

Shaohua Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Predictive Biomarker ◽

Breast Cancer Patients ◽

Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-011-0260-0 ◽

2011 ◽

Vol 17 (2) ◽

pp. 96-104 ◽

Cited By ~ 54

Author(s):

Naoki Hayashi ◽

Seigo Nakamura ◽

Yasuharu Tokuda ◽

Yuji Shimoda ◽

Hiroshi Yagata ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Prognostic Value ◽

Metastatic Breast ◽

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy

Annals of Oncology ◽

10.1093/annonc/mdr434 ◽

2012 ◽

Vol 23 (5) ◽

pp. 1144-1150 ◽

Cited By ~ 67

Author(s):

A. Giordano ◽

M. Giuliano ◽

M. De Laurentiis ◽

G. Arpino ◽

S. Jackson ◽

...

Keyword(s):

Breast Cancer ◽

Targeted Therapy ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra

Annals of Oncology ◽

10.1016/s0923-7534(20)32905-7 ◽

2012 ◽

Vol 23 ◽

pp. ix124-ix125 ◽

Cited By ~ 2

Author(s):

J. Cortes ◽

S. Swain ◽

I. Kudaba ◽

M. Hauschild ◽

T. Patel ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”

Annals of Oncology ◽

10.1093/annonc/mdy529 ◽

2019 ◽

Vol 30 (6) ◽

pp. 1017

Author(s):

J. Baselga ◽

A. Manikhas ◽

J. Cortés ◽

A. Llombart ◽

L. Roman ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Trial